ESTIMATED CLINICAL AND ECONOMIC IMPACT OF REDUCING BLOOD CULTURE CONTAMINATION

Understand the update of the National Patient Safety Goals to be sure your organization is in compliance with the requirements. Each year healthcare providers must meet the requirements of the Joint Commission's National Patient Safety Goals as part of the accreditation process. Receive an overview and update of the 2019 National Patient Safety Goals. Receive practical advice to implement the goals. Failing to meet a requirement will result in a requirement for improvement. This information is critical to ensure you are aware of the requirements.

Triple-negative breast cancer accounts for a disproportionate share of the total breast cancer morbidity rate due to its aggressive behavior and lack of effective targets.Join Dr. Brian Adams of Harvard Medical School as he discusses how microRNAs can serve as superior therapeutic agents in the fight against triple negative breast cancer.

Genome-editing enzymes such as CRISPR-Cas9 have been successfully employed to target different genetic disorders in model systems, and ex vivo approaches have demonstrated the clinical potential of this technology. However, the challenge of delivering such corrective enzymes in vivo represents a substantial barrier to therapeutic translation. Viral vectors—refined during their use in traditional gene therapy—represent the most widely-used delivery platform in preclinical work, and nanoparticles are quickly maturing into a comparably powerful vehicle. Direct delivery of pre-formed CRISPR enzymes has recently emerged as an appealing strategy for enabling therapeutic editing in vivo. In this GEN webinar, we will hear how the Wilson lab works to advance this approach by performing molecular engineering, giving CRISPR enzymes the properties necessary for safe, efficient, and accessible delivery in a clinical setting. These efforts will enable in vivo delivery of CRISPR enzymes, including hard-to-deliver tools such as base editors and prime editors.

Industry guidelines for host cell protein impurity analysis emphasize the importance of process-specific and product-specific assessment to account for how the purification procedures and the therapeutic product may uniquely influence the impurities observed. HCP-Mass Spectrometry (HCP-MS) analysis is quickly becoming recognized as a practical, orthogonal approach to ELISA to achieve greater coverage and knowledge of the HCP profile of a biopharmaceutical product. Establishing a streamlined workflow for HCP-MS analysis can be challenging, given that the strategies and rationale for implementing HCP-MS will differ depending on the product, process(es) and other project-specific variables. This webinar will highlight the benefits and the limitations of key analysis criteria for scientists who are developing their HCP-MS detection strategy.